SEARCH

SEARCH BY CITATION

References

  • Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK (2008) Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 30: 11- 25
  • Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prsospective identification of tumourigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983- 3988
  • Arumugam T, Ramachandran V, Fourneir KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820- 5828
  • Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756- 760
  • Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730- 737
  • Cameron S, Dahler A, Jabbar I, Endo-Munoz L, Thomas G, Poth K, Rickwood D, Guminski A, Saunders N (2010) Tumour initiating activity and tumour morphology of HNSCC is modulated by interactions between clonal variants within the tumour. Lab Invest 90: 1594- 1603
  • Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108: 7950- 7955
  • Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67: 1979- 1987
  • Chonghaile TN, Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27 (Suppl 1): S149- S157
  • Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann New York Acad Sci 1218: 3- 14
  • DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 52- 65
  • Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9- 22
  • DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68: 8643- 8653
  • Devita VT, Schein PS (1973) The use of drugs in combination for the treatment of cancer: rationale and results. New Engl J Med 288: 998- 1006
  • Dicker AJ, Serewko MM, Russell T, Rothnagel JA, Strutton GM, Saunders NA (2002) Isolation, from a basal cell carcinoma, of a functionally distinct fibroblast-like cell type, that overexpresses ptch. J Invest Dermatol 118: 859- 865
  • Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506- 510
  • Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirstrom K, Magnusson K, Ebert BL, et al (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 121: 784- 799
  • Eng C, Leone G, Orloff MS, Ostrowski MC (2009) Genomic alterations in tumor stroma. Cancer Res 69: 6759- 6764
  • Engelman JA (2009) Targetting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550- 562
  • Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, De long LM, Wooley K, Guminski A, et al (2012) Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106: 107- 115
  • Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman AA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 363: 809- 819
  • Fodale V, Pierobon M, Liotta L, Petricon E (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17: 9- 95
  • Fukuda Y, Schuetz JD (2012) ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol 83: 1073- 1083
  • Garraway LA, Janne PA (2012) Circumventing cancer drug resistance in the era of personalised medicine. Cancer Discov 2: 214- 226
  • Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111- 222
  • Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366: 883- 892
  • Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, et al (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213s- 6216s
  • Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633- 644
  • Haar CP, Hebbar P, Wallace GC, Das A, Vandergrift WA, Smith JA, Giglio P, Patel SJ, Ray SK, Banik NL (2012) Drug resistance in glioblastoma: a mini review. Neurochem Res 37: 1192- 1200
  • Hsu DSS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chiang CC, Tzeng CH, Wu KJ, Kao JY, et al (2010) Regulation of excision repair cross-complementation group 1 by snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 16: 4561- 4571
  • Hu M, Yao J, Cai L, Bachman KE, Brule F, Velculescu V, Polyak K (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37: 899- 905
  • Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869- 873
  • Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Rev 25: 521- 529
  • Kolodner RD, Cleveland DW, Putnam CD (2011) Aneuploidy drives a mutator phenotype in cancer. Science 333: 942- 943
  • Kwak EL, Bang YJ, Carnidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693- 1703
  • Latifi A, Abubaker K, Castrechini N, Ward AC, Lionque C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, et al (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112: 2850- 2864
  • Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri M, Dick J (1994) A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367: 645- 648
  • Leung CT, Brugge JS (2012) Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 482: 410- 414
  • Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030- 1037
  • McConkey DJ, Choi W, Marquis L, Martin F, Williams SB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al (2009) Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28: 335- 344
  • Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267- 1270
  • Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958- 969
  • Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584- 593
  • Muranen T, Selfors LM, Worster DT, Iwanicki MC, Song L, Morales FC, Gao S, Mills GB, Grugge JS (2012) inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21: 227- 239
  • Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al (2011) Tumour evolution inferred by single cell sequencing. Nature 472: 90- 94
  • Nieto MA (2011) The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 16.1- 16.30
  • Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457- 1461
  • Paez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Waktsuki T, Loupakis F, Lenz HJ (2012) Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 18: 645- 653
  • Place AE, Huh SJ, Polyak K (2011) The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 13: 227- 237
  • Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117: 3155- 3163
  • Poth K, Guminski A, Thomas G, Jabbar I, Saunders NA (2010) Treatment with cisplatin induces a transient increase in tumourigenic potential in resistant HNSCC cells. Mol Cancer Ther 9: 2430- 2439
  • Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973- 978
  • Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targetting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418- 429
  • Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, et al (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40: 650- 655
  • Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M (2010) A Temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583- 594
  • Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M (2012) Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 82: 159- 170
  • Ruiz C, Lenkiewicz E, evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, et al (2011) Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci USA 108: 12054- 12059
  • Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722- 4729
  • Sansing HA, Sarkeshik A, Yates JR, Patel V, Gutkind JS, Yamada KM, Berrier AL (2011) Integrin αβ1, ανβ, α6β effectors p130Cas, Src and talin regulate carcinoma invasion and resistance. Biochem Biophys Res Commun 406: 171- 176
  • Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance. Nat Med 5: 662- 668
  • Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822- 829
  • Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al (2011) Mosaic amplification of multiple recepttor tyrosine kinase genes in glioblastoma. Cancer Cell 20: 810- 817
  • Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK (2009) Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459: 428- 433
  • Takata M, Morita R, Takehara K (2000) Clonal heterogeneity in sporadic melanomas as revealed by loss of heterozygosity analysis. Int J Cancer 85: 492- 497
  • Tang DG (2012) understanding cancer stem cell heterogeneity and plasticity. Cell Res 22: 457- 472
  • Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455- 9462
  • Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843- 854
  • Thompson EW, Haviv I (2011) The social aspects of EMT-MET plasticity. Nat Med 17: 1048- 1049
  • Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf TH (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104: 1691- 1696
  • Villanueva J, Vultur A, Lee JT, Somasundaram R, Kalabis MF, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargetting MEK and IGF-1R/PI3K. Cancer Cell 18: 683- 695
  • Weaver VM, lelievre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, Werb Z, Bissell MJ (2002) β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205- 216
  • Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108- 1113
  • Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJH, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, et al (2012) Clonal selection drives genetic divergence of metatstatic medulloblastoma. Nature 482: 529- 533
  • Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, et al (2012) Single-cell exome sequencing reveals singl-nucleotide mutation characteristics of a kidney tumor. Cell 148: 886- 895
  • Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al (2010) TGF-{beta} IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107: 15535- 15540
  • Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686- 8698